

ProbioMed™ 100

100B CFU Shelf-Stable, Broad-Spectrum Probiotics



By David M. Brady, ND, DACBN, IFMCP, FACN and Kendra Whitmire, MS, CNS

This information is provided as a medical and scientific educational resource for the use of physicians and other licensed health-care practitioners ("Practitioners"). This information is intended for Practitioners to use as a basis for determining whether to recommend these products to their patients. All recommendations regarding protocols, dosing, prescribing, and/or usage instructions should be tailored to the individual needs of the patient considering their medical history and concomitant therapies. This information is not intended for use by consumers.

Designs for Health's ProbioMed™ 100 consists of 10 highly researched probiotic strains in a unique moisture-resistant, desiccant-lined packaging to ensure strain survivability without the need for refrigeration. The diversity and clinically significant quantities of these specific strains target gastrointestinal (GI) health to support common GI conditions, bowel function, and varying degrees of dysbiosis associated with lifestyle or life stage, antibiotic therapy, dietary imbalance, or stress.* This family of products also possesses specific strains that have strong immunomodulatory actions to mature and enhance the immune system during all life stages. ProbioMed™ 100 is clinically effective for continuous replenishment and stabilization of microbiota.*

Common problems associated with probiotic supplementation include strain identification and disclosure of individual counts, strain integrity and stability during storage and internal delivery, resistance/tolerance to stomach acid and bile salts, adherence to intestinal walls, and antibiotic resistance. These highly potent formulations have been developed to address these common challenges and maximize their effectiveness. Each probiotic strain and count have been carefully selected after an extensive review of scientific literature to ensure superior viability in low pH conditions and the presence of bile salts, with proven adherence to human epithelial and mucosal surfaces, and antibiotic resistance.

Highlights

- Combines 10 boutique strains at therapeutically significant dosages
- Evidence-based formulations using researched and validated strains
- Specific strain identification with disclosed CFU count
- Significant overage ensures long shelf life and guarantees delivery of stated CFU count
- State-of-the-art moisture, oxygen, and light-resistant, desiccant-lined packaging to protect probiotics and extend shelf life, and to eliminate the need for refrigeration
- Superior tolerance and resistance to stomach acid and bile salts
- Capsules featuring delayed-release technology for optimal survivability from stomach acid and properly timed release of the probiotics in the lower GI tract
- Strong adherence to intestinal epithelial and mucosal walls
- Does not cause antibiotic resistance
- Dairy-free formulations

Ingredient Highlights

Lactobacillus acidophilus (DDS®-1) is a potent immunomodulatory probiotic strain shown to promote immune activity by increasing regulatory T cells, inducing chemokine and cytokine response, stimulating dendritic cells to promote T helper type (Th)1/Th2/Th3 immunity, and improving immunoglobulin (Ig)A response. It also supports butyrate and other short-chain fatty acid (SCFA) production, downregulates inflammatory cytokines, supports the abundance of other beneficial bacteria, and enables immune maturation in fetal enterocytes. Additionally, studies have found it to have superior survival and adhesion rates.¹⁻⁷

L. acidophilus has also been shown to improve microbiome diversity after antibiotic therapy. Studies demonstrate that *L. acidophilus* DDS®-1 alone or as part of a probiotic combination significantly improves colitis and abdominal pain, normalizes bowel movements in irritable bowel syndrome (IBS), improves abdominal symptoms of lactose intolerance, improves atopic dermatitis in children, supports faster improvement in functional constipation, shortens acute respiratory infections in children, reduces incidence and duration of cold and flu symptoms, and moderates effects of anticipatory stress due to night shift work.⁷⁻¹⁹

Lactobacillus plantarum (UALp-05™) significantly inhibits the invasion of pathogenic *E. coli*, especially when combined with other probiotic strains, and it effectively reduces disturbance of the microbiome resulting from antibiotic therapy.^{19,20} Studies show it reduces abdominal pain, bloating, and other GI symptoms associated with IBS and colitis.^{21,22}

Benefits*

- Clinically effective for continuous replenishment and stabilization of microbiota
- Supports a healthy immune response
- Supports normal bowel movements
- Supports a healthy GI system
- Supports recovery from antibiotic treatment

Supplement Facts

Serving Size 1 capsule

Amount Per Serving	% Daily Value
Probiotic Blend	517 mg (100 billion CFU) *
<i>Bifidobacterium lactis</i> (UABla-12™)	36.4 billion CFU *
<i>Lactobacillus acidophilus</i> (DDS®-1)	10.8 billion CFU *
<i>Lactobacillus plantarum</i> (UALp-05™)	18.0 billion CFU *
<i>Lactobacillus casei</i> (UALc-03™)	7.2 billion CFU *
<i>Bifidobacterium breve</i> (UABbr-11™)	7.2 billion CFU *
<i>Lactobacillus salivarius</i> (UALs-07™)	6.0 billion CFU *
<i>Lactobacillus rhamnosus</i> (GG)	6.0 billion CFU *
<i>Lactobacillus paracasei</i> (UALpc-04™)	6.0 billion CFU *
<i>Bifidobacterium bifidum</i> (UABb-10™)	1.2 billion CFU *
<i>Bifidobacterium longum</i> (UABl-14™)	1.2 billion CFU *

*Daily Value not established.

Other Ingredients: Microcrystalline cellulose, delayed release capsule (hydroxypropyl methylcellulose, gellan gum), vegetable stearate, silica.

It has also been shown to have good resistance in the digestive tract, along with adhesion and immunomodulatory effects, including upregulating anti-inflammatory interleukin (IL)-10 and downregulating IL-8 cytokine production.⁴ As an immunomodulatory agent, *L. plantarum* enhances the immunoglobulin (Ig)G response and improves the body's response to influenza, especially in the elderly.^{23,24}

***Bifidobacterium lactis* (UABla-12™)** has been present in human food for decades and is broadly recognized for its key role in the human intestinal microflora throughout life. Its anti-inflammatory properties are useful in attenuating the symptoms of colitis and supporting the body against allergies and allergic rhinitis.^{22,25} It protects and restores the microbiome after antibiotic therapy and boosts the body's IgG response.^{11,25} It has been found to support colitis, atopic dermatitis, acute respiratory infections in children, the stress associated with night shifts, functional constipation, and IBS, especially in combination with *L. acidophilus* DDS®-1.^{7,14-18}

***Lactobacillus casei* (UALC-03™)** improves systemic and mucosal immune responses, reducing the occurrence of infections, especially in the elderly.^{25,26} Its anti-inflammatory properties are noted as it lowers high-sensitivity C-reactive protein (hsCRP), reduces the occurrence of necrotizing enterocolitis, modifies the expression of toll-like receptor in ulcerative colitis, and repairs aspirin-induced bowel injury.²⁷⁻³¹ *L. casei* also may improve insulin sensitivity and support healthy glucose metabolism.³²

***Bifidobacterium breve* (UABbr-11™)** is a normal commensal microorganism that prevents and improves constipation, abdominal bloating, and anal itch, burn, and pain. It also helps to improve other symptoms of ulcerative colitis and necrotizing enterocolitis.^{31,33,34} It may also support healthy fasting glucose and hsCRP while increasing plasma glutathione.³⁵

***Lactobacillus paracasei* (UALpc-04™)** can inhibit pathogenic *Salmonella*, *S. aureus*, *E. coli*, and listeria while protecting and restoring the microbiome after antibiotic therapy.¹¹ As an immunomodulatory agent, it induces IL-10, (TNF)-α, (IFN)-γ, and IL-12, and enhances the IgG and IgM response.²³ Studies have found that the immunomodulating properties may support atopic dermatitis and peripheral immune responses in celiac disease.^{36,37} Colitis models show a significant reduction in intestinal inflammation with *L. paracasei* therapy.^{38,39} It has also been shown to benefit IBS.⁴⁰

***Lactobacillus salivarius* (UALs-07™)** mitigates inflammatory symptoms and modulates cytokine production and the cellular response to pathogenic challenges while restoring a disrupted microbiome.^{11,41} It also improves oral health by reducing gum bleeding and physiologic halitosis while increasing resistance to dental caries.^{42,43}

***Lactobacillus rhamnosus* (GG)** is a potent immunomodulatory strain that increases interleukin and cytokine production, inhibits tumor necrosis factor-alpha (TNF-α), phagocytosis and natural killer cell activity, secretory IgA (the form found in secretions), inhibits the production of lipopolysaccharides (LPS) or endotoxins, supports fetal immunity, and imparts some of the immunomodulatory components of breast milk. It also produces a beneficial biofilm that can protect the mucosa to support intestinal epithelial integrity.⁴⁴ Studies have found it beneficial for IBD, diarrhea especially in children, acute gastroenteritis in children, functional GI disorders, antibiotic-associated diarrhea, allergies, IBS, and upper respiratory infections in children.⁴⁴⁻⁵⁰

***Bifidobacterium bifidum* (UABb-10™)** improves functional constipation and symptoms of IBS, including abdominal pain, bloating, belching, flatulence, and diarrhea.⁵¹ The improvement in functional constipation was also observed when used in combination with *L. acidophilus* DDS-1® and *B. lactis* UABla12™ and *B. longum* UABl14™.⁷ Upper gastrointestinal symptoms associated with *H. pylori* infections also benefit from *B. bifidum*.⁵¹

***Bifidobacterium longum* (UABI-14™)** improves the composition and metabolic activities of colonic bacterial communities and immune parameters, helping the symptomatic effects of celiac disease, IBS, and functional constipation.^{51,52,53} Studies show *B. longum* significantly reduces TNF-α, C-reactive protein, serum aspartate aminotransferase, insulin resistance, serum endotoxin, and steatosis in patients with non-alcoholic steatohepatitis.⁵⁴ The improvement in functional constipation was also observed when used in combination with *L. acidophilus* DDS-1® and *B. lactis* UABla12™ and *B. bifidum* UABb-10™.⁷

Recommended Use: Take 1 capsule per day with a meal or as directed by your health-care practitioner.

For a list of references cited in this document, please visit:

<https://www.designsforhealth.com/api/library-assets/literature-reference---probiomed-100-tech-sheet-references>



DDS® and all UA™ codes are trademarks of UAS Laboratories, LLC and used under license.

***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.**

To contact Designs for Health, please call us at (860) 623-6314, or visit us on the web at www.designsforhealth.com.

References

1. Petersen ER, Claesson MH, Wedebye Schmidt EG, et al. Consumption of probiotics increases the effect of regulatory T cells in transfer colitis. *Inflamm Bowel Dis*. 2012;18(11):131-142. doi:10.1002/ibd.21709.
2. Zeuthen LH, Fink LN, Metzdorff SB, et al. *Lactobacillus acidophilus* induces a slow but more sustained chemokine and cytokine response in naïve foetal enterocytes compared to commensal *Escherichia coli*. *BMC Immunol*. 2010;11:2. doi.org/10.1186/1471-2172-11-2.
3. Chen C-C, Chiu C-H, Lin T-Y, Shi HN, Walker WA. Effect of probiotics *Lactobacillus acidophilus* on *Citrobacter rodentium* colitis: The role of dendritic cells. *Pediatr Res*. 2009;65(2):169-175.
4. Vemuri R, Shinde T, Shastri MD, et al. A human origin strain *Lactobacillus acidophilus* DDS-1 exhibits superior *in vitro* probiotic efficacy in comparison to plant or dairy origin probiotics. *Int J Med Sci*. 2018;15(9):840-848. doi:10.7150/ijms.25004.
5. Vemuri R, Gundamaraju R, Shinde T, et al. *Lactobacillus acidophilus* DDS-1 modulates intestinal-specific microbiota, short-chain fatty acid and immunological profiles in aging mice. *Nutrients*. 2019;11(6):1297. doi:10.3390/nu11061297.
6. Vemuri R, Shinde T, Gundamaraju R, et al. *Lactobacillus acidophilus* DDS-1 modulates the gut microbiota and improves metabolic profiles in aging mice. *Nutrients*. 2018;10(9):1255. doi:10.3390/nu10091255.
7. Martoni CJ, Evans M, Chow CT, Chan LS, Leyer G. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: a randomized controlled trial. *J Dig Dis*. 2019;20(9):435-446. doi:10.1111/1751-2980.12797.
8. Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. *Pediatrics*. 2009;124:e172-e179. doi:10.1542/peds.2008-2666.
9. Saber R, Zadeh M, Pakanati KC, Bere P, Klaenhammer T, Mohamadzadeh M. Lipoteichoic acid-deficient *Lactobacillus acidophilus* regulates downstream signals. *Immunotherapy*. 2011;3(3):337. doi.org/10.2217/imt.10.119.
10. Björklund, Ouwehand AC, Forssten SD, et al. Gut microbiota of healthy elderly NSAID users is selectively modified with the administration of *Lactobacillus acidophilus* NCFM and lactitol. *Age (Dordr)*. 2011;34(4):987-999. doi:10.1007/s11357-011-9294-5.
11. Engelbrektsen A, Korzeniki JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. *J Med Microbiol*. 2009;58:663-670. doi:10.1099/jmm.0.47615-0.
12. Waitzberg DL, Logullo LC, Bittencourt AF, et al. Effect of synbiotic in constipated adult women – a randomized, double-blind, placebo-controlled study of clinical response. *Clin Nutr*. 2013;32(1):27-33. doi:10.1016/j.clnu.2012.08.010.
13. Ouwehand AC, Tiihonen K, Saarinen M, Putaala H, Rautonen N. Influence of a combination of *Lactobacillus acidophilus* NCFM and lactitol on healthy elderly: intestinal and immune parameters. *Br J Nutr*. 2009;101:367-375. doi:10.1017/S0007114508003097.
14. Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. *Am J Clin Dermatol*. 2010;11(5):351-361. doi:10.2165/11531420-000000000-00000.
15. Martoni CJ, Srivastava S, Leyer GJ. *Lactobacillus acidophilus* DDS-1 and *Bifidobacterium lactis* UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial. *Nutrients*. 2020;12(2):363. doi:10.3390/nu12020363.
16. Pakdaman MN, Udani JK, Molina JP, Shahani M. The effects of the DDS-1 strain of *Lactobacillus* on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial. *Nutr J*. 2016;15(1):56. doi:10.1186/s12937-016-0172-y.
17. Gerasimov SV, Ivantsiv VA, Bobryk LM, et al. Role of short-term use of *L. acidophilus* DDS-1 and *B. lactis* UABLA-12 in acute respiratory infections in children: a randomized controlled trial. *Eur J Clin Nutr*. 2016;70(4):463-469. doi:10.1038/ejcn.2015.171.
18. West NP, Hughes L, Ramsey R, et al. Probiotics, anticipation stress, and the acute immune response to night shift. *Front Immunol*. 2021;11:599547. doi:10.3389/fimmu.2020.599547.
19. Polewski MA, Krueger CG, Reeda JD, Leyer G. Ability of cranberry proanthocyanidins in combination with a probiotic formulation to inhibit *in vitro* invasion of gut epithelial cells by extra-intestinal pathogenic *E. coli*. *J Funct Foods*. 2016;25:123-134. doi:10.1016/j.jff.2016.05.015.

20. Lönnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I. Intake of *Lactobacillus plantarum* reduces certain gastrointestinal symptoms during treatment with antibiotics. *J Clin Gastroenterol*. 2010;44(2):106-112. doi:10.1097/mcg.0b013e3181b2683f.
21. Nobaek S, Johansson M-L, Göran M, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *Am J Gastroenterol*. 2000;95(5):1231-1238. doi:10.1016/s0002-9270(00)00807-8.
22. Foligne B, Nutten S, Grangette C, et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. *World J Gastroenterol*. 2007;13(2):236. doi:10.3748/wjg.v13.i2.236.
23. Paineau D, Carcano D, Leyer G, et al. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. *FEMS Immunol Med Microbiol*. 2008;53:107-113. doi:10.1111/j.1574-695X.2008.00413.x.
24. Bosch M, Méndez M, Pérez M, Farran A, Fuentes MC, Cuñé J. *Lactobacillus plantarum* CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly. *Nutr Hosp*. 2012;27(2):504-509. doi:10.1590/S0212-16112012000200023.
25. Ouwehand, Nermes M, Collado MC, Rautonen N, Salminen S, Isolauri E. Specific probiotics alleviate allergic rhinitis during the birch pollen season. *World J Gastroenterol*. 2009;15(26):3261-3268. doi:10.3748/wjg.15.3261.
26. Rizzardini G, Eskesen D, Calder PC, Capetti A, Jespersen L, Clerici M. Evaluation of the immune benefits of two probiotic strains *Bifidobacterium animalis* ssp. *lactis*, BB-12® and *Lactobacillus paracasei* ssp. *paracasei*, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. *Br J Nutr*. 2012;107(6):876-884. doi:10.1017/S000711451100420X.
27. Guillemard E, Tondu F, Lacoïn F, Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic *Lactobacillus casei* DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. *Br J Nutr*. 2010;103(1):58-68. doi:10.1017/S0007114509991395.
28. Alipour B, Homayouni-Rad Z, Vaghef-Mehrabany E, et al. Effects of *Lactobacillus casei* supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. *Int J Rheum Dis*. 2014;17(5):519-27. doi:10.1111/1756-185X.12333.
29. Endo H, Higurashi T, Hosono K, et al. Efficacy of *Lactobacillus casei* treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. *J Gastroenterol*. 2011;46(7):894-905. doi:10.1007/s00535-011-0410-1.
30. D'Inca, Barollo M, Scarpa M, et al. Rectal administration of *Lactobacillus casei* DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. *Dig Dis Sci*. 2011;56(4):1178-1187. doi:10.1007/s10620-010-1384-1.
31. Braga TD, da Silva GA, de Lira PI, de Carvalho Lima M. Efficacy of *Bifidobacterium breve* and *Lactobacillus casei* oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. *Am J Clin Nutr*. 2011;93(1):81-86. doi: 10.3945/ajcn.2010.29799.
32. Hulston CJ, Churnside AA, Venables MC. Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. *Br J Nutr*. 2015;113(4):596-602. doi:10.1017/S0007114514004097.
33. Ishikawa H, Matsumoto S, Ohashi Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. *Digestion*. 2011;84(2):128-133. doi:10.1159/000322977.
34. Del Piano M, Carmagnola S, Anderloni A, et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools: a double-blind, randomized, placebo-controlled study. *J Clin Gastroenterol*. 2010;44(suppl 1):S30-S34. doi:10.1097/MCG.0b013e3181ee31c3.
35. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmailzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. *Ann Nutr Metab*. 2013;63(1-2):1-9. doi:10.1159/000349922.
36. Håkansson Å, Andrén Aronsson C, Brundin C, Oscarsson E, Molin G, Agardh D. Effects of *Lactobacillus plantarum* and *Lactobacillus paracasei* on the peripheral immune response in children with celiac disease autoimmunity: a randomized, double-blind, placebo-controlled clinical trial. *Nutrients*. 2019;11(8):1925. doi:10.3390/nu11081925.
37. Kim WK, Jang YJ, Han DH, et al. *Lactobacillus paracasei* KBL382 administration attenuates atopic dermatitis by modulating immune response and gut microbiota. *Gut Microbes*. 2020;12(1):1-14. doi:10.1080/19490976.2020.1819156.
38. Chen CL, Hsu PY, Pan TM. Therapeutic effects of *Lactobacillus paracasei* subsp. *paracasei* NTU 101 powder on dextran sulfate sodium-induced colitis in mice. *J Food Drug Anal*. 2019;27(1):83-92. doi:10.1016/j.jfda.2018.05.004.
39. Pan T, Guo HY, Zhang H, Liu AP, Wang XX, Ren FZ. Oral administration of *Lactobacillus paracasei* alleviates clinical symptoms of colitis induced by dextran sulphate sodium salt in BALB/c mice. *Benef Microbes*. 2014;5(3):315-322. doi:10.3920/BM2013.0041.
40. Lewis ED, Antony JM, Crowley DC, et al. Efficacy of *Lactobacillus paracasei* HA-196 and *Bifidobacterium longum* R0175 in alleviating symptoms of irritable bowel syndrome (IBS): a randomized, placebo-controlled study. *Nutrients*. 2020;12(4):1159. doi:10.3390/nu12041159.

41. Neville BA, O'Toole PW. Probiotic properties of *Lactobacillus salivarius* and closely related *Lactobacillus* species. *Future Microbiol.* 2010;5:759-774. doi:10.2217/fmb.10.35.
42. Iwamoto T, Suzuki N, Tanabe K, Takeshita, Hirofuji T. Effects of probiotic *Lactobacillus salivarius* WB21 on halitosis and oral health: an open-label pilot trial. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2010;110(2):201-208. doi:10.1016/j.tripleo.2010.03.032.
43. Nishihara T, Suzuki N, Yoneda M, Hirofuji T. Effects of *Lactobacillus salivarius*-containing tablets on caries risk factors: a randomized open-label clinical trial. *BMC Oral Health.* 2014;14:110. doi:10.1186/1472-6831-14-110.
44. Capurso L. Thirty years of *Lactobacillus rhamnosus* GG: a review. *J Clin Gastroenterol.* 2019;53(suppl 1):S1-S41. doi:10.1097/MCG.0000000000001170.
45. Szajewska H, Kołodziej M. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults. *Aliment Pharmacol Ther.* 2015;42(10):1149-1157. doi:10.1111/apt.13404.
46. Li YT, Xu H, Ye JZ, et al. Efficacy of *Lactobacillus rhamnosus* GG in treatment of acute pediatric diarrhea: a systematic review with meta-analysis. *World J Gastroenterol.* 2019;25(33):4999-5016. doi:10.3748/wjg.v25.i33.4999.
47. Szajewska H, Kołodziej M, Gieruszczak-Białek D, Skórka A, Ruszczyński M, Shamir R. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG for treating acute gastroenteritis in children – a 2019 update. *Aliment Pharmacol Ther.* 2019;49(11):1376-1384. doi:10.1111/apt.15267
48. Pedersen N, Andersen NN, Végh Z, et al. Ehealth: low FODMAP diet vs *Lactobacillus rhamnosus* GG in irritable bowel syndrome. *World J Gastroenterol.* 2014;20(43):16215-16226. doi:10.3748/wjg.v20.i43.16215
49. Liu S, Hu P, Du X, Zhou T, Pei X. *Lactobacillus rhamnosus* GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. *Indian Pediatr.* 2013;50(4):377-381. doi:10.1007/s13312-013-0123-z.
50. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: *Lactobacillus rhamnosus* GG for abdominal pain-related functional gastrointestinal disorders in childhood. *Aliment Pharmacol Ther.* 2011;33(12):1302-1310. doi:10.1111/j.1365-2036.2011.04665.x
51. Miki K, Urita Y, Ishikawa F, et al. Effect of *Bifidobacterium bifidum* fermented milk on *Helicobacter pylori* and serum pepsinogen levels in humans. *J Dairy Sci.* 2007;90(6):2630-2640. doi:10.3168/jds.2006-803.
52. Olivares M, Castillejo G, Varea V, Sanz Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of *Bifidobacterium longum* CECT 7347 in children with newly diagnosed coeliac disease. *Br J Nutr.* 2014;112(1):30-40.
53. Macfarlane S, Cleary S, Bahrami B, Reynolds N, Macfarlane GT. Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study. *Aliment Pharmacol Ther.* 2013;38(7):804-816.
54. Malaguarnera M, Vacante M, Antic T, et al. *Bifidobacterium longum* with fructo-oligosaccharides in patients with non-alcoholic steatohepatitis. *Dig Dis Sci.* 2012;57(2):545-553.